Kinki-chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka 591-8555, Japan.
Lung Cancer. 2011 Aug;73(2):211-6. doi: 10.1016/j.lungcan.2010.12.014. Epub 2011 Jan 26.
We investigated survival potential in patients receiving erlotinib after failure of gefitinib, focusing on response and time to progression (TTP) with gefitinib.
We retrospectively reviewed lung adenocarcinoma patients who received erlotinib after experiencing progression with gefitinib. Our primary objective was to evaluate the prognostic significance of erlotinib therapy.
A total 42 lung adenocarcinoma patients were included in this study. Overall disease control rate was 59.5% (partial response [PR], 2.4%; stable disease [SD], 57.1%). Median overall survival was 7.1 months, and median progression-free survival was 3.4 months. The number of patients who achieved PR and non-PR (SD+ progressive disease [PD]) with gefitinib were 22 (52%) and 20 (48%), respectively. Patients with PR for gefitinib showed significantly longer survival times than those with non-PR (9.2 vs. 4.7 months; p=0.014). In particular, among PR patients, those with TTP <12 months on gefitinib showed significantly longer survival times than those with TTP ≥12 months (10.3 vs. 6.4 months; p=0.04).
Erlotinib may exert survival benefit for lung adenocarcinoma patients with less than 12 months of TTP of prior gefitinib who achieved PR for gefitinib.
我们研究了吉非替尼治疗失败后接受厄洛替尼治疗的患者的生存潜力，重点关注吉非替尼的缓解率和无进展生存期（TTP）。
我们回顾性分析了接受厄洛替尼治疗的肺腺癌患者，这些患者在接受吉非替尼治疗后出现进展。我们的主要目的是评估厄洛替尼治疗的预后意义。
本研究共纳入 42 例肺腺癌患者。总体疾病控制率为 59.5%（部分缓解[PR]，2.4%；稳定疾病[SD]，57.1%）。中位总生存期为 7.1 个月，中位无进展生存期为 3.4 个月。吉非替尼治疗达到 PR 和非 PR（SD+进展性疾病[PD]）的患者分别为 22 例（52%）和 20 例（48%）。吉非替尼 PR 的患者生存时间明显长于非 PR 患者（9.2 个月 vs. 4.7 个月；p=0.014）。特别是，在 PR 患者中，吉非替尼 TTP<12 个月的患者生存时间明显长于 TTP≥12 个月的患者（10.3 个月 vs. 6.4 个月；p=0.04）。
对于 TTP<12 个月的肺腺癌患者，如果在接受吉非替尼治疗时达到 PR，则厄洛替尼可能会带来生存获益。
